Renflexis Vs xeljanz medication

In individuals with moderately to highly active rheumatoid arthritis, Renflexis, when used with methotrexate, can enhance physical function, lessen signs and symptoms, and assist prevent additional joint destruction. Additionally, it can treat Psoriatic Arthritis, lessen the signs and symptoms of current arthritis, assist in preventing additional joint deterioration, and enhance physical function in psoriatic arthritis patients.

One of four biosimilars of Remicade, Renflexis is a biological medication (infliximab). Remicade biosimilars are very close but not identical copies of the medication that are intended to have the same effect.

Renflexis works in the same way as the other versions of infliximab, by blocking the damage that results from too much tumour necrosis factor-alpha (TNF-alpha). Renflexis binds to TNF-alpha, which stops it from interacting with its receptors and activating certain processes.

XELJANZ has been prescribed for more than 9 years, since initial approval in 2012, for adults with moderate to severe rheumatoid arthritis.† XELJANZ was approved to treat adults with active psoriatic arthritis† in 2017, adults with moderate to severe ulcerative colitis† in 2018, and adults with active ankylosing spondylitis in 2021.

XELJANZ is a Janus kinase (JAK) inhibitor that helps disrupt JAK pathways from inside the cells, which are believed to play a role in inflammation. Watch to learn more about the science of XELJANZ and how JAK inhibitors are thought to work.